 NEWTOWN, Pa., Feb. 01, 2021 GLOBE NEWSWIRE -- Helius Medical Technologies, Inc. Nasdaq:HSDT TSX:HSM Helius or the Company, a neurotech company focused on neurological wellness, announced today the closing of an underwritten public offering of units for gross proceeds of approximately 11.0 million, which includes the full exercise of the underwriters over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Helius. 